Roche Vabysmo Sales Surpassed USD 4 Billion In 2024
Portfolio Pulse from
Roche's Vabysmo sales have exceeded USD 4 billion in 2024, capturing over 35% of the global bispecific antibodies market, according to Kuick Research.
January 07, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's Vabysmo has achieved sales exceeding USD 4 billion in 2024, representing more than 35% of the global bispecific antibodies market, indicating strong market performance and potential revenue growth for Roche.
The significant sales figure of over USD 4 billion and the market share of more than 35% in the bispecific antibodies market highlight Vabysmo's strong performance. This is likely to positively impact Roche's revenue and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100